Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Key Highlights
- ➤Regeneron (REGN) expects approximately $270 million from extended BARDA agreement
- ➤Additional Inmazeb doses will be delivered to the U.S. government through 2031
- ➤Maftivimab added to PARTNERS trial for potential Bundibugyo virus treatment
- ➤Inmazeb reduced mortality approximately 55% versus active control in low-viral-load patients
Expert Statements
Leonard S. Schleifer, Board Co-Chair, President and Chief Executive Officer of Regeneron
“Maintaining a ready supply of Inmazeb is exactly the kind of preparedness this country needs for the threats we can already see on the horizon”
Leonard S. Schleifer, Board Co-Chair, President and Chief Executive Officer of Regeneron
“This extended agreement reflects the strength of our long-standing collaboration with BARDA and our shared commitment to ensuring that at-the-ready medicines are available whenever an Ebola outbreak occurs.”
George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer of Regeneron
“Inmazeb was created by Regeneron scientists in record time using our proprietary VelociSuite® rapid-response technologies”
George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer of Regeneron
“We are now advancing maftivimab, which has already demonstrated positive results in non-human primates infected with Bundibugyo, so that we can bring another potential Ebola treatment forward as quickly as possible to help in the current outbreak.”
George D. Yancopoulos, Board Co-Chair, President and Chief Scientific Officer of Regeneron
“Regeneron’s continued supply of Inmazeb to the U.S. government, our advancement of maftivimab and our partnerships to support frontline response capacity reflect the Company’s long-term commitment to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks.”
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million
TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb(®) (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers, and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA's original procurement of the treatment in 2020.
Get started
Create a free account to read the full story.